SCHEMBL23536576

SCHEMBL23536576

CC(O)c1ccc(S(=O)(=O)N(C)C)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
LMNA P02545 4/20 0.52
HTT P42858 1/20 0.52
GAA P10253 1/20 0.49
NR1I2 O75469 1/20 0.47
MAPT P10636 2/20 0.42
KDM4E B2RXH2 1/20 0.42
KMT2A Q03164 1/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA3 P07451 1/20 0.41
CA4 P22748 1/20 0.41
CA6 P23280 1/20 0.41
CA5A P35218 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA13 Q8N1Q1 1/20 0.41
CA14 Q9ULX7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4734618 0.83 LMNA (0.55) ALDH1A1SMN1; SMN2LMNAHTTGAA
SCHEMBL6810966 0.80 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2LMNAHTTGAA
SCHEMBL23723351 0.78 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2LMNAHTTGAA
SCHEMBL23554550 0.78 MEN1 (0.52) ALDH1A1SMN1; SMN2LMNAHTTGAA
SCHEMBL23536615 0.78 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2LMNAHTTGAA
SCHEMBL11990198 0.77 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2LMNAHTTGAA
SCHEMBL12509658 0.77 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2LMNAHTTGAA
SCHEMBL14239243 0.77 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2LMNAHTTGAA
SCHEMBL13264889 0.77 ENPP2 (0.54) LMNAKMT2A
SCHEMBL10863214 0.77 LMNA (0.50) ALDH1A1SMN1; SMN2LMNAHTTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230416262-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. 2023-12-28 US disclosed
EP-4192957-A2 TRPML MODULATORS Casma Therapeutics, Inc. (US) 2023-06-14 EP disclosed
CN-116113698-A TRPML modulators 卡斯玛治疗公司 2023-05-12 CN disclosed
WO-2022032073-A2 TRPML MODULATORS CASMA THERAPEUTICS, INC. (US) 2022-02-10 WO disclosed
WO-2021127333-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. (US) 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230416262-A1 TRPML MODULATORS TRPM2, TRPM4, TRPM5 ALDH1A1 3737/4885SMN1; SMN2 1776/4885LMNA 3324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.